Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity

Overweight and Obesity Clinical Trial

— OASIS 2  

Official title:

Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in East Asian Participants With Overweight or Obesity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05132088
• Other study ID #: NN9932-4738
• Secondary ID: U1111-1258-7561
• Status: Completed
• Phase: Phase 3
• Start date: November 16, 2021
• Est. completion date: September 1, 2023

Study information

• Verified date: September 2023
• Source: Novo Nordisk A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight.

This study will look at the change in participants' body weight. Participants will either get semaglutide tablets (new medicine) or placebo tablets ('dummy' medicine that looks like semaglutide but has no effect on the body). For a fair comparison, people are divided into two groups at random by a computer. This process is called randomisation.

Semaglutide tablets are new medicine being tested to treat overweight and obesity. Doctors in many countries can already prescribe semaglutide tablets at lower doses to treat type 2 diabetes.

Participants will get semaglutide or placebo tablets for 68 weeks and will need to take 1 tablet every morning.

In addition to taking the medicine, participants will have talks with study staff about:

• healthy food choices

• how to be more physically active

• what participants can do to lose weight The study will last for about 1½ year. Participants will have 14 clinic visits and 7 phone calls with the study healthcare professional.

Blood samples will be taken at 12 visits. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period. If participants are a woman and are able to become pregnant, participants will be checked for pregnancy via urine tests.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 201
• Est. completion date: September 1, 2023
• Est. primary completion date: July 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

Participants are eligible to be included in the study only if all the following criteria apply:

• Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.

• Male or female, age above or equal to 18 years at the time of signing informed consent

• Body mass index (BMI) of greater than or equal to 27.0 kg/m^2 with greater than or equal to 2 weight related comorbidities (treated or untreated) according to the JASSO guideline or BMI greater than or equal to 35.0 kg/m^2 with greater than or equal to1 weight related comorbidity (treated or untreated) according to the JASSO guideline. At least one comorbidity should be hypertension, dyslipidaemia or type 2 diabetes (T2D)

• History of at least one self-reported unsuccessful dietary effort to lose body weight

For participants with T2D at screening the following inclusion criteria apply in addition to criteria 1-4:

• Diagnosed with T2D greater than or equal to 180 days prior to screening

• Treated with either diet and exercise alone or stable treatment (same drug(s), dose and dosing frequency) for at least 60 days prior to the day of screening with up to 3 oral antidiabetic drugs (OADs) alone or in any combination (metformin, a-glucosidase (AGI), sulphonylureas (SU), glinides, SGLT2i (sodium-glucose co-transporter 2 inhibitor) or thiazolidinediones)

• HbA1c 7.0-10.0% (53-86 mmol/mol) (both inclusive) as measured by central laboratory at screening

Exclusion criteria:

Participants without T2D only:

• HbA1c greater than or equal to 6.5% (48 mmol/mol) as measured by the central laboratory at screening

• History of type 1 or type 2 diabetes

• Treatment with glucose-lowering agent(s) within 90 days prior to screening

• Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of eGFR brlow 15 ml/min/1.73 m^2 according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by kidney disease improving global outcomes (KDIGO) 2012 classification by the central laboratory at screening

Participants with T2D at screening only:

• Treatment with any medication for the indication of diabetes other than stated in the inclusion criteria within the past 60 days prior to screening

• Receipt of any other anti-diabetic investigational drug within 90 days prior to screening for this study, or receipt of any investigational drugs not affecting diabetes within 30 days prior to screening for this study

• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed by an ophthalmologist or another suitably qualified health care provider within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

• Renal impairment measured as eGFR value of below 30 mL/min/1.73 m^2 according to CKD EPI creatinine equation as defined by KDIGO 2012 classification by the central laboratory at screening

• In participants treated with SGLT2i, renal impairment measured as eGFR value of below 60 mL/min/1.73 m^2 according to CKD EPI creatinine equation as defined by KDIGO 2012 classification by the central laboratory at screening

The following criteria apply to all participants:

Obesity-related:

• Treatment with any medication indicated for weight management within 90 days prior to screening

• Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed: (1) liposuction and/or abdominoplasty, if performed greater than 1 year prior to screening, (2) lap banding, if the band has been removed greater than 1 year prior to screening, (3) intragastric balloon, if the balloon has been removed greater than 1 year prior to screening or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed greater than 1 year prior to screening

• Uncontrolled thyroid disease per investigators discretion

• A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

Related Conditions & MeSH terms

• Obesity
• Overweight
• Overweight and Obesity

Intervention

Drug:
• semaglutide 50 mg
Participants will have semaglutide for 68 weeks and will have 1 tablet every morning. Dose gradually increased to 50 mg.
• placebo (semaglutide)
Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.

Locations

Country	Name	City	State
Japan	Novo Nordisk Investigational Site	Ibaraki
Japan	Novo Nordisk Investigational Site	Minato-ku, Tokyo
Japan	Novo Nordisk Investigational Site	Osaka
Japan	Novo Nordisk Investigational Site	Osaka
Japan	Novo Nordisk Investigational Site	Sapporo city	Hokkaido
Japan	Novo Nordisk Investigational Site	Suita-shi	Osaka
Japan	Novo Nordisk Investigational Site	Tokyo
Japan	Novo Nordisk Investigational Site	Tokyo
Japan	Novo Nordisk Investigational Site	Yamato-shi	Kanagawa
Korea, Republic of	Novo Nordisk Investigational Site	Daegu
Korea, Republic of	Novo Nordisk Investigational Site	Gyeonggi-do
Korea, Republic of	Novo Nordisk Investigational Site	Incheon
Korea, Republic of	Novo Nordisk Investigational Site	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

Japan,  Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relative change in body weight	Percentage-point	From baseline (week 0) to end of treatment (week 68)
Primary	Achievement of body weight reduction greater than or equal to 5% (Yes/No)	Count of participants	At end of treatment (week 68)
Secondary	Achievement of body weight reduction greater than or equal to 10% (Yes/No)	Count of participants	At end of treatment (week 68)
Secondary	Change in Physical function domain (5-items) score (IWQOL-Lite-CT)	Score points	From baseline (week 0) to end of treatment (week 68)
Secondary	Achievement of body weight reduction greater than or equal to 15% (Yes/No)	Count of participants	At end of treatment (week 68)
Secondary	Achievement of body weight reduction greater than or equal to 20% (Yes/No)	Count of participants	At end of treatment (week 68)
Secondary	Change in body mass index (BMI)	Count of participants	From baseline (week 0) to end of treatment (week 68)
Secondary	Change in waist circumference measured according to the JASSO guideline	Messured in CM	From baseline (week 0) to end of treatment (week 68)
Secondary	Change in Visceral Fat Area (VFA) measured by CT scan in a subset of the Japanese study population	%-point	From baseline to end of treatment (week 68)
Secondary	Change in Visceral Fat Area (VFA) measured by CT scan in a subset of the Japanese study population	Messured in cm^2	From baseline to end of treatment (week 68)
Secondary	Change in systolic blood pressure	Messured in mmHg	From baseline (week 0) to end of treatment (week 68)
Secondary	Change in diastolic blood pressure	Messured in mmHg	From randomisation (week 0) to end of treatment (week 68)
Secondary	Change in glycated haemoglobin (HbA1c)	%-point	From baseline (week 0) to end of treatment (week 68)
Secondary	Change in lipids: Total cholesterol	Ratio to baseline	From baseline (week 0) to end of treatment (week 68)
Secondary	Change in lipids: high density lipoprotein (HDL) cholesterol	Ratio to baseline	From baseline (week 0) to end of treatment (week 68)
Secondary	Change in lipids: low-density lipoprotein (LDL) cholesterol	Ratio to baseline	From baseline (week 0) to end of treatment (week 68)
Secondary	Change in lipids: very-low density lipoprotein (VLDL) cholesterol	Ratio to baseline	From baseline (week 0) to end of treatment (week 68)
Secondary	Change in lipids: Triglycerides	Ratio to baseline	From baseline (week 0) to end of treatment (week 68)
Secondary	Change in lipids: Free fatty acids	Ratio to baseline	From baseline (week 0) to end of treatment (week 68)
Secondary	Change in high sensitivity C Reactive Protein	Ratio to baseline	From baseline (week 0) to end of treatment (week 68)
Secondary	Number of treatment emergent adverse events	Count of events	From baseline (week 0) to end of study (week 75)
Secondary	Number of serious adverse events	Count of events	From baseline (week 0) to end of study (week 75)